Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shadia Zaman

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Hematology & Oncology|December 12, 2013
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell linesCornel Joseph Phillip, Shadia Zaman, Shujun Shentu, et al.
Annals of Hematology|March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myelomaMuhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerAsma Dilawari, Mirat Shah, Gwynn Ison, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Hematology & Oncology|December 12, 2013
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell linesCornel Joseph Phillip, Shadia Zaman, Shujun Shentu, et al.
Annals of Hematology|March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myelomaMuhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerAsma Dilawari, Mirat Shah, Gwynn Ison, et al.
Pageof 2